The novel technology now tested for detecting plactonic and biofilm-forming bacteria growth, cellular activities in metabolic diseases, slow growing mycobacteria, bacterial growth in fresh water production and distribution, fungal pathogens in agricultural development programs and anti-parasite drug development for tropical diseases
Symcel: 23 June 2016: Symcel, the company behind the revolutionary cell-based assay tool, calScreener™, has unveiled the scale of growth, over a four year period, in the diverse range of biological applications that its groundbreaking technology has been tested for. This coincides with the company’s keynote presention being delivered this week at the 2016 XIX ISBC (International Society of biological Calorimetry) conference taking place this week in Basel.
The calScreener solution is proven to provide high sample throughput, combined with small sample volumes and pre-sterilized consumables, to facilitate the growth and analysis of mammalian cells, bacteria and other living matter. To date, the technology has been tested for monitoring both planktonic and biofilm-forming bacterial growth and the detection of slow growing mycobacteria. The technology is also used to test bacterial growth in fresh water production and distribution, fungal pathogens in agricultural development programs and anti-parasite drug development for tropical diseases. Moreover, the technology is used to monitor cellular activities in metabolic disease and adipose tissue differentiation. Additionally, CalSreener has been tested to detect the killing potency of mAb development.
Magnus Jansson, Chief Scientific Officer at Symcel commented: “one of the key goals in testing a wide variety of potential applications has been to find areas where our patented calScreener technology can make the largest impact. Thus far, the most favorable areas for its uptake have been in bacterial detection, especially for the monitoring of biofilm formation, antibacterial compound screening and also in the field of metabolic diseases research.”
Christer Wallen, CEO of Symcel commented: “What we conclude from the testing and applications development so far undertaken is that given the right setting, it is far easier to convince a wider audience that calorimetry base cell assays can provide novel insights into research that are simply not possible to achieve from conventional technology. Furthermore, we have concluded that calorimetry is ready for a large breakthrough in modern cell biological research – no longer confined to a smaller group of users.”
For media enquiries, please contact Tristan jervis or Alex Heeley at De Facto Communications on +44 (0) 203 735 8166 or e-mail t.jervis@defacto.com.
Notes to Editors
SymCel website address: http://www.symcel.se/.
SymCel Company Info
SymCel provides a novel cell-based assay tool for real time cellular bioenergetics measurements. SymCel is a privately held biotechnology company located in the Kista region of Stockholm Sweden, a region well known for high tech telecom and med-tech industry development.
SymCel was founded by Dr Dan Hallen and Prof. Ingemar Wadsö in 2004. The founders have an extensive background in the field of calorimetry measurement and technology development. The current research team at SymCel has over 62 years of experience from many disciplines within the biotechnology industry as well as the pharmaceutical development industry.
SymCel develops and markets analytical instrumentations that fulfil an unmet need for cell biological research and development, within R&D departments of Life Science industry, as well as academic research laboratories. Our solution is a fast label-free assay technology providing real-time continuous data monitoring of cell metabolism.
